Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

Immunoglobulin light chain (AL) amyloidosis is the most common acquired systemic amyloidoses. Its presentation is often insidious and progressive, which may delay diagnosis. The interval between first symptoms and actual diagnosis along the intrinsic heterogeneity of tissue tropism create a wide spectrum of presentations, both in terms of scope and depth of symptoms and signs and functional status of patients. In this review, the authors review the pathogenesis, diagnosis and differential diagnosis of AL amyloidosis along with the prognosis and state-of-the-art management for patients with this affliction.

Multiple 3D inversion recovery imaging for volume T1 mapping of the heart

In this article, a three-dimensional inversion recovery sequence was optimized with the aim of generating in vivo volume T(1) maps of the heart using a 1.5-T MR system. Acquisitions were performed before and after gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA) administration in one patient with hypertrophic cardiomyopathy and in two healthy volunteers. Data were acquired with a multishot fast field echo readout using both ECG and respiratory triggers. A dedicated phantom, composed of four solutions with different T(1) values, was positioned on the subjects' thoracic region to perform patient-specific calibration. Pixel based T(1) maps were calculated with a custom Matlab(®) code. Phantom measurements showed a good accuracy of the technique and in vivo T(1) estimation of liver, skeletal muscle, myocardium, and blood resulted in good agreement with values reported in the literature. Multiple three-dimensional inversion recovery technique is a feasible and accurate method to perform T(1) volume mapping.

Cardiac MR imaging of nonischemic cardiomyopathies: imaging protocols and spectra of appearances

Recent technologic advances in cardiac magnetic resonance (MR) imaging have resulted in images with high spatial and temporal resolution and excellent myocardial tissue characterization. Cardiac MR is a valuable imaging technique for detection and assessment of the morphology and functional characteristics of the nonischemic cardiomyopathy. It has gained acceptance as a standalone imaging modality that can provide further information beyond the capabilities of traditional modalities such as echocardiography and angiography. Black-blood fast spin-echo MR images allow morphologic assessment of the heart with high spatial resolution, while T2-weighted MR images can depict acute myocardial edema. Contrast material-enhanced images can depict and be used to quantify myocardial edema, infiltration, and fibrosis. This review presents recommended cardiac MR protocols for and the spectrum of imaging appearances of the nonischemic cardiomyopathies.

Cardiac magnetic resonance imaging for stage B heart failure

Cardiac magnetic resonance imaging (CMR) can play a key role in the assessment and follow-up of patients with stage B heart failure. CMR currently serves as the reference standard for quantifying right and left ventricular size and ejection fraction. Technical advances have also enabled CMR to provide noninvasive tissue characterization and detailed assessments of myocardial performance. Thus, in addition to standard metrics of cardiac structure and function, CMR offers a variety of tools for determining cause, severity, and estimating the prognosis associated with an asymptomatic cardiomyopathy.

Cardiovascular magnetic resonance in the evaluation of heart failure: a luxury or a need?

Heart failure is a common syndrome with multiple causes. Cardiovascular magnetic resonance (CMR), using the available range of technique, is establishing itself as the gold standard noninvasive test for determining the underlying causes, and adding prognostic value, guiding therapy. Progress is continuing and rapid with promising new techniques such as diffuse fibrosis assessment. This article discusses the diverse roles of CMR in heart failure.

Cardiovascular magnetic resonance: applications in daily practice

Over the last 10 years, the development of newer pulse sequences and applications in new clinical areas has enabled cardiovascular magnetic resonance to emerge as a powerful tool for the physicians to both diagnose and guide treatments of various cardiac pathologies. The greatest strengths of cardiovascular magnetic resonance include the assessment of ischemia and viability, evaluation of nonischemic cardiomyopathies, including myocarditis, pericardial disease, congenital heart disease, and tissue characterization of cardiac masses.

The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy

Cardiovascular magnetic resonance imaging (CMR) plays an increasing role in the assessment of patients with various cardiovascular disorders. Given its enhanced spatial resolution, improved tissue characterization, and lack of ionizing radiation, it has become the test of choice in the evaluation of patients with new-onset cardiomyopathy of unknown etiology. In this paper, we will review the role of CMR in the evaluation of patients with various types of non-ischemic cardiomyopathy.

The role of cardiac MR in new-onset heart failure

In patients with heart failure, cardiovascular magnetic resonance imaging (CMR) allows a multifaceted approach to cardiac evaluation by enabling an assessment of morphology, function, perfusion, viability, tissue characterization, and blood flow during a single comprehensive examination. Given its accuracy and reproducibility, many believe CMR is the reference standard for the noninvasive assessment of ventricular volumes, mass, and function, and offers an ideal means for the serial assessment of disease progression or treatment response in individual patients. Delayed-enhancement (DE)-CMR provides a direct assessment of myopathic processes. This permits a fundamentally different approach than that traditionally taken to ascertaining the etiology of cardiomyopathy, which is vital in patients with nonischemic cardiomyopathy and incidental coronary artery disease and patients with mixed, ischemic and nonischemic cardiomyopathy. Precise tissue characterization with DE-CMR also improves the diagnosis of left ventricular thrombus, for which it is the emerging clinical reference standard. There is a growing body of literature on the utility of CMR for patient risk stratification, and its potential role in important management decisions such as for cardiac resynchronization therapy and defibrillator placement.

The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy

The onset of sudden cardiac death and large inter- and intra-familial clinical variability of hypertrophic cardiomyopathy pose an important clinical challenge. Cardiac magnetic resonance imaging is a high-resolution imaging modality that has become increasingly available in the past decade and has the unique possibility to demonstrate the presence of fibrosis or scar using late gadolinium enhancement imaging. As a result, the diagnostic and prognostic potential of cardiac magnetic resonance imaging has been extensively explored in acute and chronic ischaemic cardiomyopathy, as well as in several nonischaemic cardiomyopathies.This review aims to provide a critical overview of recently published studies on hypertrophic cardiomyopathy and discusses the role of cardiac magnetic resonance imaging in differentiating underlying causes of hypertrophic cardiomyopathy, such as familial hypertrophic cardiomyopathy, cardiac involvement in systemic disease and left ventricular hypertrophy due to endurance sports. Also, it demonstrates the use of cardiac magnetic resonance in risk stratification for the onset of sudden cardiac death, and early identification of asymptomatic family members of hypertrophic cardiomyopathy patients who are at risk for the development of hypertrophic cardiomyopathy. (Neth Heart J 2010;18:135-43.).

Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis

OBJECTIVES

Using cardiac magnetic resonance imaging (MRI) we tested the diagnostic value of various markers for amyloid infiltration.

METHODS

We performed MRI at 1.5 T in 36 consecutive patients with cardiac amyloidosis and 48 healthy volunteers. The protocol included cine imaging, T2-weighted spin echo, T1-weighted spin echo before and early after contrast and late gadolinium enhancement. We compared the frequency of abnormalities and their relation to mortality.

RESULTS

Median follow-up was 31 months. Twenty-three patients died. Mean left ventricular (LV) mass was 205 ± 70 g. LV ejection fraction (EF) was 55 ± 12%. T2 ratio was 1.5 ± 0.4. 33/36 patients had pericardial and 22/36 had pleural effusions. All but two had heterogeneous late enhancement. Surviving patients did not differ from those who had died with regard to gender, LV mass or volume. Surviving patients had a significantly higher LVEF (60.4 ± 9.9% vs. 51.6 ± 11.5%; p = 0.03). The deceased patients had a lower T2 ratio than those who survived (1.38 ± 0.42 vs. 1.76 ± 0.17; p = 0.005). Low T2 was associated with shorter survival (Chi-squared 11.3; p < 0.001). Cox regression analysis confirmed T2 ratio < 1.5 as the only independent predictors for survival.

CONCLUSION

Cardiac amyloidosis is associated with hypointense signal on T2-weighted images. A lower T2 ratio was independently associated with shortened survival.

Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance

BACKGROUND

Heart failure remains a major cause of mortality in thalassaemia major. The possible role of cardiac fibrosis in thalassemia major in the genesis of heart failure is not clear. It is also unclear whether cardiac fibrosis might arise as a result of heart failure.

METHODS

We studied 45 patients with thalassaemia major who had a wide range of current cardiac iron loading and included patients with prior and current heart failure. Myocardial iron was measured using T2* cardiovascular magnetic resonance (CMR), and following this, late gadolinium enhancement (LGE) was used to determine the presence of macroscopic myocardial fibrosis.

RESULTS

The median myocardial T2* in all patients was 22.6 ms (range 5.3-58.8 ms). Fibrosis was detected in only one patient, whose myocardial T2* was 20.1 ms and left ventricular ejection fraction 57%. No fibrosis was identified in 5 patients with a history of heart failure with full recovery, in 3 patients with current left ventricular dysfunction undergoing treatment, or in 18 patients with myocardial iron loading with cardiacT2* < 20 ms at the time of scan.

CONCLUSION

This study shows that macroscopic myocardial fibrosis is uncommon in thalassemia major across a broad spectrum of myocardial iron loading. Importantly, there was no macroscopic fibrosis in patients with current or prior heart failure, or in patients with myocardial iron loading without heart failure. Therefore if myocardial fibrosis indeed contributes to myocardial dysfunction in thalassemia, our data combined with the knowledge that the myocardial dysfunction of iron overload can be reversed, indicates that any such fibrosis would need to be both microscopic and reversible.

MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy

OBJECTIVE

The purpose of this study was to evaluate cardiac MRI features in a group of patients with transthyretin familial amyloid polyneuropathy (FAP).

SUBJECTS AND METHODS

Sixteen patients with transthyretin FAP underwent 2D echocardiography with Doppler examination, cardiac MRI, and (99m)Tc-diphosphonate (DPD) scintigraphy. Four patients had peripheral polyneuropathy, three had carpal tunnel syndrome, one patient had symptoms and signs of heart failure, and eight patients had no symptoms but had a family history of FAP. At MRI, cardiac function parameters and delayed contrast enhancement findings were evaluated.

RESULTS

Six patients had cardiac radiotracer uptake at scintigraphy (FAP cardiac group), and 10 patients had no cardiac uptake (FAP noncardiac group). The FAP cardiac group included the four patients with peripheral neuropathy, one patient with carpal tunnel syndrome, and the only patient with heart failure. At MRI, abnormal contrast enhancement was found in all patients with positive scintigraphic findings and in no patient with negative scintigraphic findings. All patients had involvement of the left ventricle and other chambers or structures (atria, right ventricle, tricuspid valve leaflets). Left ventricular contrast enhancement was focal in four patients, subendocardial circumferential in one patient, and diffuse in one patient. The only patient with signs of heart failure had circumferential subendocardial enhancement.

CONCLUSION

Cardiac contrast-enhanced MRI can be used to identify cardiac amyloidosis in patients with FAP who do not have clinical signs of heart involvement. In these patients, the typical subendocardial circumferential pattern of contrast enhancement is rare. We observed unusual enhancement patterns as focal or diffuse left ventricular enhancement accompanied by enhancement of the atria, tricuspid valve, or right ventricle.

Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold

BACKGROUND

T1 mapping allows direct in-vivo quantitation of microscopic changes in the myocardium, providing new diagnostic insights into cardiac disease. Existing methods require long breath holds that are demanding for many cardiac patients. In this work we propose and validate a novel, clinically applicable, pulse sequence for myocardial T1-mapping that is compatible with typical limits for end-expiration breath-holding in patients.

MATERIALS AND METHODS

The Shortened MOdified Look-Locker Inversion recovery (ShMOLLI) method uses sequential inversion recovery measurements within a single short breath-hold. Full recovery of the longitudinal magnetisation between sequential inversion pulses is not achieved, but conditional interpretation of samples for reconstruction of T1-maps is used to yield accurate measurements, and this algorithm is implemented directly on the scanner. We performed computer simulations for 100 ms

RESULTS

We found good agreement between the average ShMOLLI and MOLLI estimates for T1 < 1200 ms. In contrast to the original method, ShMOLLI showed no dependence on heart rates for long T1 values, with estimates characterized by a constant 4% underestimation for T1 = 800-2700 ms. In-vivo, ShMOLLI measurements required 9.0 ± 1.1 s (MOLLI = 17.6 ± 2.9 s). Average healthy myocardial T1 s by ShMOLLI at 1.5T were 966 ± 48 ms (mean ± SD) and 1166 ± 60 ms at 3T. In MI patients, the T1 in unaffected myocardium (1216 ± 42 ms) was similar to controls at 3T. Ischemically injured myocardium showed increased T1 = 1432 ± 33 ms (p < 0.001). The difference between MI and remote myocardium was estimated 15% larger by ShMOLLI than MOLLI (p < 0.04) which suffers from heart rate dependencies for long T1. The in-vivo variability within ShMOLLI T1-maps was only 14% (1.5T) or 18% (3T) higher than the MOLLI maps, but the MOLLI acquisitions were twice longer than ShMOLLI acquisitions.

CONCLUSION

ShMOLLI is an efficient method that generates immediate, high-resolution myocardial T1-maps in a short breath-hold with high precision. This technique provides a valuable clinically applicable tool for myocardial tissue characterisation.

Collapse

Key Words Collapse

MESH Headings

• Adult
• Algorithms
• Cardiac-Gated Imaging Techniques/instrumentation
• Computer Simulation
• Contrast Media
• Electrocardiography
• England
• Female
• Gadolinium DTPA
• Heart Rate
• Humans
• Image Interpretation, Computer-Assisted
• Magnetic Resonance Imaging/instrumentation
• Male
• Middle Aged
• Myocardial Infarction/pathology
• Myocardial Infarction/physiopathology
• Phantoms, Imaging
• Predictive Value of Tests
• Reproducibility of Results
• Respiratory Mechanics
• Time Factors

Collapse

Grants

• G0701128 Medical Research Council

Collapse

Affiliation(s)

Stefan K Piechnik University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK
Vanessa M Ferreira University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK Stephenson CMR Centre, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada
Erica Dall'Armellina University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK
Lowri E Cochlin Dept. of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
Andreas Greiser Siemens AG Healthcare Sector, Erlangen, Germany
Stefan Neubauer University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK
Matthew D Robson University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK

Collapse

Cardiac magnetic resonance imaging as a prognostic tool in patients with nonischemic cardiomyopathy

Technical advancements have enabled cardiac magnetic resonance (CMR) imaging to provide a noninvasive assessment of cardiomyopathy. Cardiac magnetic resonance imaging acts as the reference standard for quantifying left and right ventricular function. It also assesses the etiology of cardiomyopathy by demonstrating the presence and size of myocardial scar and by detecting myocardial inflammation and interstitial infiltration. Cardiomyopathy can result in early mortality and arrhythmic risk, and CMR imaging aids in risk stratification among this group of patients. Left ventricular ejection fraction predicts which patients will benefit most from implantable cardioverter-defibrillators (ICDs), but this is not a perfect marker of arrhythmic risk. The etiology of cardiomyopathy, as assessed with CMR imaging, adds further prognostic information with infiltrative cardiomyopathies, resulting in higher mortality than idiopathic cardiomyopathies. Among patients with nonischemic cardiomyopathy (NICM), the degree of fibrosis as determined by the CMR imaging sequence of late gadolinium enhancement (LGE) imaging offers further prognostic information. Late gadolinium enhancement imaging in patients with NICM portends an approximately 3- to 8-fold greater risk of death or hospitalization than NICM without LGE imaging. Further research is needed to determine if the presence of LGE will be helpful in predicting which patients may benefit from ICD implantation.

Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging

BACKGROUND

Cardiac involvement is one of the most important prognostic factors in systemic AL amyloidosis. The aim of our study was to assess the role of cardiovascular magnetic resonance (CMR) imaging in prognosis evaluation in AL amyloidosis.

METHODS

We retrospectively analyzed 29 consecutive patients with AL amyloidosis who had undergone CMR. Clinical, laboratory, echocardiographic, and CMR characteristics were compared between CMR-positive (ie, with CMR signs of cardiac localization of AL amyloidosis) and CMR-negative patients. Univariate and multivariate analyses were performed to assess the prognostic value of positive CMR in comparison with other prognostic factors.

RESULTS

CMR was positive in 11 patients (38%). The overall survival rates for CMR-positive patients were 28%, 14%, and 14% versus 84%, 77%, and 45% at 1, 2, and 5 years, respectively, for CMR-negative patients (P=.002). Late gadolinium enhancement patterns, biventricular hypertrophy, and pericardial effusion on CMR were more frequent in nonsurvivors. Congestive heart failure, abnormal echocardiography, Eastern Cooperative Oncology Group grade >1, brain natriuretic peptide, and left ventricular ejection fraction <55% also were associated with a decreased survival. The presence of congestive heart failure was the only significant variable associated with survival on multivariate analysis.

CONCLUSION

We found that the presence of a positive CMR in AL amyloidosis was associated with a significantly increased risk of death, in particular of cardiac origin, but was not independent of clinical congestive heart failure.

Cardiac MRI evaluation of nonischemic cardiomyopathies

The purpose of this manuscript is to review the major MRI findings in patients with nonischemic cardiomyopathies. Cardiac MRI has become an integral part in the diagnosis and management of patients with nonischemic cardiomyopathies. Findings on cardiac MRI studies can help distinguish between different types of cardiomyopathies and can provide valuable diagnostic and prognostic information.

[Restrictive cardiomyopathy versus constrictive pericarditis in patients with diastolic dysfunction: MR imaging features]

Restrictive cardiomyopathies are characterized by diastolic dysfunction while systolic function is usually preserved. MRI is helpful by its ability to characterize tissues, especially the demonstration of interstitial or nodular fibrosis based on the underlying etiology. In the presence of constrictive pericarditis from pericardial inflammation, fibrosis or calcifications, diastolic expansion is impaired resulting in poor diastolic ventricular filling, resulting in a characteristic type of diastolic impairment, adiastole. MRI can demonstrate the underlying anatomical lesion: pericardial thickening, though the presence of a pericardium or normal thickness does not entirely exclude the possibility of constriction. As such, the presence of additional imaging features such as abnormal right ventricular shape, vena cava dilatation, and paradoxical movement of the intraventricular septum, during operator-guided deep respiration.

Review of Journal of Cardiovascular Magnetic Resonance 2009

There were 56 articles published in the Journal of Cardiovascular Magnetic Resonance in 2009. The editors were impressed with the high quality of the submissions, of which our acceptance rate was about 40%. In accordance with open-access publishing, the articles go on-line as they are accepted with no collating of the articles into sections or special thematic issues. We have therefore chosen to briefly summarise the papers in this article for quick reference for our readers in broad areas of interest, which we feel will be useful to practitioners of cardiovascular magnetic resonance (CMR). In some cases where it is considered useful, the articles are also put into the wider context with a short narrative and recent CMR references. It has been a privilege to serve as the Editor of the JCMR this past year. I hope that you find the open-access system increases wider reading and citation of your papers, and that you will continue to send your quality manuscripts to JCMR for publication.

Cardiac amyloidosis: approaches to diagnosis and management

Amyloidosis is a clinical disorder caused by the extracellular deposition of misfolded, insoluble aggregated protein with a characteristic ss pleated sheet configuration that produces apple-green birefringence under polarized light when stained with Congo red dye. The spectrum of organ involvement can include the kidneys, heart, blood vessels, central and peripheral nervous systems, liver, intestines, lungs, eyes, skin, and bones. Cardiovascular amyloidosis can be primary, a part of systemic amyloidosis, or the result of chronic systemic disease elsewhere in the body. The most common presentations are congestive heart failure because of restrictive cardiomyopathy and conduction abnormalities. Recent developments in imaging techniques and extracardiac tissue sampling have minimized the need for invasive endomyocardial biopsy for amyloidosis. Cardiac amyloidosis management will vary depending on the subtype but consists of supportive treatment of cardiac related symptoms and reducing the amyloid fibrils formation attacking the underlying disease. Despite advances in treatment, the prognosis for patients with amyloidosis is still poor and depends on the underlying disease type. Early diagnosis of cardiac amyloidosis may improve outcomes but requires heightened suspicion and a systematic clinical approach to evaluation. Delays in diagnosis, uncertainties about the relative merits of available therapies, and difficulties in mounting large-scale clinical trials in rare disorders combine to keep cardiac amyloidosis a challenging problem. This review outlines current approaches to diagnosis, assessment of disease severity, and treatment of cardiac amyloidosis.

Gadolinium pharmacokinetics of chronic myocardial infarcts: Implications for late gadolinium-enhanced infarct imaging

PURPOSE

To monitor gadolinium pharmacokinetics in the hearts of patients with chronic myocardial infarcts and to determine the variability of contrast agent concentrations and accuracy of infarct detection over an hour time period.

MATERIALS AND METHODS

Twenty-five patients with chronic myocardial infarcts were examined. T1 measurements were performed every 2 minutes using an inversion recovery CINE balanced steady-state free precession technique. Paired differences in T1 values over time for the discrimination between the left ventricular (LV) bloodpool, viable, and infarct myocardium were statistically evaluated. The average change per 1, 5, and 10 minutes of the inversion time parameter for optimal nulling of viable myocardium was calculated. Receiver operator characteristic (ROC) curve analysis was performed to compare the performance of late gadolinium-enhanced infarct imaging at increasing delays after contrast agent administration.

RESULTS

Significantly different T1 values were reached after 10 minutes between the LV bloodpool, infarcted, and viable myocardium. The T1 difference between myocardial infarcts and the LV bloodpool increased over time, while the difference between viable myocardium and the LV bloodpool decreased. ROC curve analysis showed a decrease in performance of a fixed T1 value to discriminate between the LV bloodpool and viable myocardium over time, while there was a marked increase in the discrimination between the LV bloodpool and infarcted myocardium.

CONCLUSION

The ability to discriminate between infarcted myocardium and the LV bloodpool improves with an increasing delay after contrast agent administration while discrimination between viable myocardium and the LV bloodpool decreases.

Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis

BACKGROUND

The prognostic value of NT-proBNP has been recognized in patients with amyloidosis complicated by cardiac involvement. We aimed to use contrast enhanced cardiac magnetic resonance imaging (CMR) to identify functional and structural alterations related to levels of NT-proBNP better to understand the mechanisms of its release in cardiac amyloidosis.

METHODS AND RESULTS

CMR was performed on a 1.5-T scanner in 34 patients with biopsy proven amyloid light chain (AL; n = 27) or hereditary transthyretin related (TTR; n = 7) amyloidosis. NT-proBNP was higher in patients with (n = 25) compared to patients without cardiac involvement (n = 9) (2931 (IQR: 972-8629; min-max: 25-27,277) pg/ml vs. 177 (IQR: 71-1431; min-max: 22-7935) pg/ml, p = 0.008). ROC analysis identified a NT-proBNP of <2426.5 pg/ml as optimal discriminator for event free survival (682 +/- 65 days). NT-proBNP did not correlate with LV- ejection fraction, end-diastolic and end-systolic volumes or stroke volume. There was a moderate correlation between NT-proBNP and LV-mass (R = 0.52, p = 0.003) and extent of late gadolinium enhancement (LGE; R = 0.41, p = 0.04).

CONCLUSIONS

This study confirms the prognostic value of NT-proBNP in patients with AL and TTR amyloidosis and provides the novel finding that NT-proBNP correlates with surrogates of myocardial amyloid burden such as LV-mass and LGE, supporting the concept of NT-proBNP as a biomarker reflecting the severity of cardiac amyloid infiltration.

The role of cardiovascular magnetic resonance imaging in heart failure

Noninvasive imaging plays a central role in the diagnosis of heart failure, assessment of prognosis, and monitoring of therapy. Cardiovascular magnetic resonance (CMR) offers a comprehensive assessment of heart failure patients and is now the gold standard imaging technique to assess myocardial anatomy, regional and global function, and viability. Furthermore, it allows assessment of perfusion and acute tissue injury (edema and necrosis), whereas in nonischemic heart failure, fibrosis, infiltration, and iron overload can be detected. The information derived from CMR often reveals the underlying etiology of heart failure, and its high measurement accuracy makes it an ideal technique for monitoring disease progression and the effects of treatment. Evidence on the prognostic value of CMR-derived parameters in heart failure is rapidly emerging. This review summarizes the advantages of CMR for patients with heart failure and its important role in key areas.

Advances in Cardiovascular MRI for Diagnostics: Applications in Coronary Artery Disease and Cardiomyopathies

BACKGROUND: Cardiac magnetic resonance (CMR) imaging has emerged as an important cardiac imaging technique for the evaluation of multiple cardiac pathologies. OBJECTIVE/METHOD: The goal of this review is to describe recent advances in techniques which have extended the potential applications of CMR. The focus will be on the clinical applications of CMR for the evaluation of coronary artery disease and heart failure/cardiomyopathies which are major causes of morbidity and mortality worldwide. CONCLUSION: CMR provides unique tissue characterization which is not available from other imaging modalities and has demonstrated important diagnostic and prognostic information in many forms of heart disease.

Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up

Background

Light chain amyloidosis (AL) is a rare plasma cell dyscrasia associated with poor survival especially in the setting of heart failure. Late gadolinium enhancement (LGE) on cardiac MRI was recently found to correlate with myocardial amyloid deposition but the prognostic role is not established. The aim is to determine the prognostic significance of LGE in AL by comparing long term survival of AL patients with and without LGE.

Methods

Twenty nine consecutive patients (14 females; 62 ± 11 years) with biopsy-proven AL undergoing cardiac MRI with gadolinium as part of AL workup were included. Survival was prospectively followed 29 months (median) following MRI and compared between those with and without LGE by Kaplan-Meier and log-rank analyses.

Results

LGE was positive in 23 subjects (79%) and negative in 6 (21%). Left ventricular ejection fraction was 66 ± 17% in LGE-positive and 69 ± 12% in LGE-negative patients (p = 0.8). Overall 1-year mortality was 36%. On follow-up, 14/23 LGE-positive and none of LGE-negative patients died (log rank p = 0.0061). Presenting New York Heart Association heart failure class was also associated with poor survival (p = 0.0059). Survival between two LGE groups stratified by heart failure class still showed a significant difference by a stratified log-rank test (p = 0.04).

Conclusion

Late gadolinium enhancement is common and is associated with poor long-term survival in light chain amyloidosis, even after adjustment for heart failure class presentation. The prognostic significance of late gadolinium enhancement in this disease may be useful in patient risk-stratification.